A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.

Trial Profile

A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms SAFARI
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2017 According to eudra record, this trial was suspended in Germany.
    • 11 Nov 2016 Planned End Date changed from 1 May 2017 to 1 May 2018.
    • 11 Nov 2016 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top